Trial reportFrontiers in medicine2026
Efficacy and safety of remimazolam besylate plus propofol for sedation in endoscopic retrograde cholangiopancreatography: a randomized controlled study.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy and safety of the new anesthetic remimazolam besylate combined with propofol in anesthesia for endoscopic retrograde cholangiopancreatography (ERCP). Methods: A total of 60 patients who underwent selective ERCP in Shifang People's Hospital were selected as the research objects. They were randomly divided into the control group (C group) and the remimazolam group (R group), with 30 cases in each group. C group was given normal saline + propofol, and R group was given remimazolam + propofol. The hemodynamic indexes, propofol dosage, sedation and analgesia effects, patient and doctor satisfaction, success rate of operation and perioperative complications of the two groups were compared. Results: The perioperative heart rate (HR) and mean arterial pressure (MAP) of R group were more stable than those of C group ( Conclusion: The application of remimazolam besylate combined with propofol in ERCP can reduce the dosage of propofol, maintain stable hemodynamics, improve sedation and analgesia effects, enhance patient and doctor satisfaction, and reduce the incidence of perioperative complications, which is an effective and safe anesthetic scheme. Clinical trial registration: https://clinicaltrials.gov/, identifier ChiCTR2300 073982.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.